drugset / Trial / NCT03230175

Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)

NCT03230175 ↗

Phase 2 Completed 32 enrolled BioTissue Holdings, Inc
NaSingle-groupOpen-labelTreatment

Summary

It is hypothesized that application of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer will, with concomitant management of infection, result in a higher proportion of wounds showing complete healing within 16 weeks of initiating therapy.

Timeline

Start
2017-10-04
Primary completion
2019-01-10
Completion
2019-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject TTAX01 Other / unclassified — Topical

Indications